adagrasib | sciencenewsnet.in

Breaking News

New research sheds light on a surprising connection between COVID-19 and cancer regression

Research finds no significant negative impact of repealing a Depression-era law allowing companies to pay workers with disabilities below minimum wage

Low-frequency magnetic field (LFMF) for enhanced carotenoids production by Rhodotorula glutinis

AAOS Sweeps Three Top Workplace Honors Locally and Nationally in 2024

Texas Tech Health El Paso Schools Recognized in U.S. News & World Report’s Best Colleges Rankings

University of Chicago Medical Center Receives 26th Consecutive “A” in Hospital Safety from Leapfrog Group

Hackensack Meridian Jersey Shore University and Hackensack University Medical Centers Achieve Excellence in Life Support Care

International Cancer Organizations Present Collaborative Work During Oncology Event in China

ETRI-F&U Credit Information Co., Ltd., Opens a New Path for AI-Based Professional Consultation

One or many? Exploring the population groups of the largest animal on Earth

15 Nov, 2024

AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer

April 8, 2024 sarah JonasResearch Results

Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.